This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Richter, E.
Right arrow Articles by Hillemann, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Richter, E.
Right arrow Articles by Hillemann, D.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, April 2007, p. 1534-1536, Vol. 51, No. 4
0066-4804/07/$08.00+0     doi:10.1128/AAC.01113-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

First Linezolid-Resistant Clinical Isolates of Mycobacterium tuberculosis{triangledown}

Elvira Richter, Sabine Rüsch-Gerdes, and Doris Hillemann*

Forschungszentrum Borstel, National Reference Center for Mycobacteria, D-23845 Borstel, Germany

Received 4 September 2006/ Returned for modification 10 October 2006/ Accepted 10 January 2007

Linezolid resistance was found in 4 (1.9%) of 210 multidrug-resistant Mycobacterium tuberculosis strains. The MICs of linezolid were 4 µg/ml (one strain) and 8 µg/ml (three strains). Since no mutations were detected in potential target genes, the mechanism of resistance remains unclear.

* Corresponding author. Mailing address: Forschungszentrum Borstel, National Reference Center for Mycobacteria, Parkallee 18, D-23845 Borstel, Germany. Phone: (49)-4537-188761. Fax: (49)-4537-188311. E-mail: dhillemann{at}fz-borstel.de

{triangledown} Published ahead of print on 22 January 2007.

Antimicrobial Agents and Chemotherapy, April 2007, p. 1534-1536, Vol. 51, No. 4
0066-4804/07/$08.00+0     doi:10.1128/AAC.01113-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Yew, W. W., Chang, K. C., Chau, C. H. (2009). Comment on: Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis. J Antimicrob Chemother 64: 1119-1119 [Full Text]  
  • Koh, W.-J., Shim, T. S. (2009). Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis--authors' response. J Antimicrob Chemother 64: 883-884 [Full Text]  
  • Feng, J., Lupien, A., Gingras, H., Wasserscheid, J., Dewar, K., Legare, D., Ouellette, M. (2009). Genome sequencing of linezolid-resistant Streptococcus pneumoniae mutants reveals novel mechanisms of resistance. Genome Res 19: 1214-1223 [Abstract] [Full Text]  
  • Coban, A. Y., Bilgin, K., Uzun, M., Akgunes, A., Yusof, A., Durupinar, B. (2008). Comparative Study for Determination of Mycobacterium tuberculosis Susceptibility to First- and Second-Line Antituberculosis Drugs by the Etest Using 7H11, Blood, and Chocolate Agar. J. Clin. Microbiol. 46: 4095-4098 [Abstract] [Full Text]  
  • Huang, T.-S., Liu, Y.-C., Sy, C.-L., Chen, Y.-S., Tu, H.-Z., Chen, B.-C. (2008). In Vitro Activities of Linezolid against Clinical Isolates of Mycobacterium tuberculosis Complex Isolated in Taiwan over 10 Years. Antimicrob. Agents Chemother. 52: 2226-2227 [Abstract] [Full Text]  
  • Hillemann, D., Rusch-Gerdes, S., Richter, E. (2008). In Vitro-Selected Linezolid-Resistant Mycobacterium tuberculosis Mutants. Antimicrob. Agents Chemother. 52: 800-801 [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»